3 (HETEROARYLOXY) - 2-ALKYL-1AZABICYCLOALKYLDERIVATE AS ALPHA.7-NACHRLIGANDEN FOR the TREATMENT OF ZNS ILLNESSES

BETA CARBOLINDERIVATE ONE AND THEIR PHARMACEUTICAL USE AGAINST DEPRESSION AND FEAR

HYDANTOIN DERIVATIVES WITH AFFINITY FOR SOMATOSTATIN RECEPTORS

ACETYLENE DERIVATIVES

1-AZA-BICYCLOÄ3.3.1ÜNONANE

SUBSTITUTED PIPERIDIN DERIVATIVES AS SOMATOSTATIN-SST1-REZEPTORANTAGONISTEN

PHENYLACETYLENDERIVATE WITH AFFINITAT TO THE MGLUR5 RECEPTOR

NEW ONE DIBENZOÄB, FÜOXEPIN-10-CARBONSÄUREAMIDE AND THEIR PHARMACEUTICAL APPLICATIONS

ACETYLENE DERIVATIVES

SEMICONDUCTOR DEVICE FOR INDIRECT DETECTION OF ELECTROMAGNETIC RADIATION AND METHOD OF PRODUCTION

The semiconductor device comprises a substrate of semiconductor material having a main surface, an integrated circuit in the substrate, a photodetector element or array of photodetector elements arranged at or above the main surface, and at least one nanomaterial film arranged above the main surface. At least part of the nanomaterial film has a scintillating property. The method of production includes the use of a solvent to apply the nanomaterial film, in particular by inject printing, by silk-screen printing, by spin coating or by spray coating. 1. A semiconductor device for detection of electromagnetic radiation , comprising:a substrate of semiconductor material having a main surface,an integrated circuit in the substrate,a nanomaterial film arranged above the main surface, at least part of the nanomaterial film having a scintillating property, anda photodetector element or array of photodetector elements arranged in the substrate at the main surface or arranged in a semiconductor layer between the main surface and the nanomaterial film, the photodetector element or array of photodetector elements being configured to detect electromagnetic radiation transformed by the nanomaterial film.2. The semiconductor device according to claim 1 , further comprising:a dielectric layer arranged between the nanomaterial film and the photodetector element or array of photodetector elements.3. The semiconductor device according to claim 1 , wherein the nanomaterial film comprises nanodots claim 1 , nanorods or nanowires or any combination thereof.4. The semiconductor device according to claim 1 , further comprising:a further nanomaterial film, at least part of the further nanomaterial film having an absorbing property and covering an area of the main surface outside the photodetector element or array of photodetector elements.5. The semiconductor device according to claim 4 , wherein the further nanomaterial film comprises nanodots claim 4 , nanorods or nanowires or any ...

1-aza-bicyclo[3.3.1]nonanes

The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R1); Y represents a group of formula, or wherein the left bond is attached to the A group and the right bond is attached to the R group; R represents a substituted or unsubstituted C5-C10aryl, substituted or unsubstituted hetero-C5-C10aryl, a group N(R1)(R4), or a group N(R2)(CHP3R4); R represent a hydrogen, C1-C4alkyl, or CF3; R2represents hydrogen, C1-C4alkyl, or CF3; R3represents hydrogen, C1-C4alkyl, or CF3; R4represents a substituted or unsubstituted C5-C10aryl or a substituted or unsubstituted C5-C10heteroaryl; in free base or acid addition salt form.

RADIATION-HARDENED PACKAGE FOR AN ELECTRONIC DEVICE

The package comprises a carrier, an electronic device arranged on the carrier, a shield arranged on the electronic device on a side facing away from the carrier, and an absorber film comprising nanomaterial applied on or above the shield. 1. A package for an electronic device , comprising:a carrier,an electronic device arranged on the carrier,a shield arranged on the electronic device on a side facing away from the carrier, andan absorber film comprising nanomaterial applied on or above the shield.2. The package of claim 1 , wherein the shield and the absorber film are only arranged on a partial area of an upper surface of the electronic device facing away from the carrier.3. The package of claim 2 , further comprising:an integrated circuit of the electronic device, the shield and the absorber film being only arranged above the integrated circuit.4. The package of claim 3 , further comprising:a transistor forming a component of the integrated circuit, the shield and the absorber film being only arranged above the transistor.5. The package of claim 1 , wherein the shield is formed from aluminum claim 1 , copper claim 1 , tungsten or a combination thereof.6. A package for an electronic device claim 1 , comprising:a carrier, andan electronic device arranged on the carrier, the electronic device being provided with a cover comprising nanomaterial, with an absorber film comprising nanomaterial, or with an adhesive layer comprising nanomaterial, anda further electronic device arranged on the carrier on a side opposite the electronic device, the further electronic device being provided with a cover comprising nanomaterial, with an absorber film comprising nanomaterial, or with an adhesive layer comprising nanomaterial.7. The package of claim 6 , whereinat least one of the electronic device and the further electronic device is provided with a cover, andthe cover comprises nanomaterial or is provided with an absorber film comprising nanomaterial.8. The package of claim 7 , ...

Macrocyclic lactams and pharmaceutical use thereof

The present invention relates to novel macrocyclic compounds of the formula, wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.

CARBOXAMIDE DERIVATIVES.

The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt or co-crystal thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

SEMICONDUCTOR IMAGE SENSOR WITH INTEGRATED PIXEL HEATING AND METHOD OF OPERATING A SEMICONDUCTOR IMAGE SENSOR

The semiconductor image sensor comprises a plurality of pixels () with photo sensors (). At least one heater () is integrated with the photo sensors and is arranged in at least one of the pixels or in the vicinity of at least one of the pixels. An appropriate operation of the heater will increase the temperature of the relevant pixel. Thus it is possible to achieve a local compensation of a temperature difference that may be due to the operation of an integrated readout circuit () or any other integrated component generating heat. 1. A semiconductor image sensor , comprising:a plurality of pixels, each pixel being provided with a photo sensor having a temperature, andat least one heater,the heater being integrated with the photo sensors, andthe heater being arranged in at least one of the pixels or in the vicinity of at least one of the pixels, so that an operation of the heater increases the temperature of the photo sensor of said pixel.2. The semiconductor image sensor of claim 1 , further comprising:at least one integrated readout circuit, whereinthe heater is arranged in the at least one of the pixels between the photo sensor of this pixel and the at least one integrated readout circuit.3. The semiconductor image sensor of claim 2 , further comprising:each further one of the pixels being provided with a further integrated readout circuit and with a further heater arranged between the further integrated readout circuit and the photo sensor of the respective further one of the pixels.4. The semiconductor image sensor of claim 1 , wherein the heater extends in at least one further pixel or in the vicinity of at least one further pixel.5. The semiconductor image sensor of claim 1 , wherein at least a further one of the pixels is provided with a further heater claim 1 , which is arranged in the further one of the pixels or in the vicinity of the further one of the pixels.6. The semiconductor image sensor of claim 1 , wherein the heater is formed by a plurality of ...

Assembly for detecting electromagnetic radiation and method of producing an assembly for detecting electromagnetic radiation

The assembly comprises a semiconductor device with an active-pixel array, a readout circuit chip or plurality of readout circuit chips mounted outside the active-pixel array, the readout circuit chip or plurality of readout circuit chips being configured to read out voltages or currents provided by the active-pixel array, and electric connections between the active-pixel array and the readout circuit chip or plurality of readout circuit chips.

ASSEMBLY FOR DETECTING ELECTROMAGNETIC RADIATION AND METHOD OF PRODUCING AN ASSEMBLY FOR DETECTING ELECTROMAGNETIC RADIATION

The assembly comprises a semiconductor device with an active-pixel array, a readout circuit chip or plurality of readout circuit chips mounted outside the active-pixel array, the readout circuit chip or plurality of readout circuit chips being configured to read out voltages or currents provided by the active-pixel array, and electric connections between the active-pixel array and the readout circuit chip or plurality of readout circuit chips.

Method of operating a semiconductor image sensor with integrated pixel heating

At least one of the pixels of the image sensor is heated using at least one heater, and the temperature of this pixel is thus increased by a larger degree than the temperature of at least a further one of the pixels.

METHOD OF OPERATING A SEMICONDUCTOR IMAGE SENSOR

At least one of the pixels of the image sensor is heated using at least one heater, and the temperature of this pixel is thus increased by a larger degree than the temperature of at least a further one of the pixels. 1. A method of operating a semiconductor image sensor with a plurality of pixels each provided with a photo sensor having a temperature , and at least one heater integrated with the photo sensors , the heater being arranged in at least one of the pixels or in the vicinity of at least one of the pixels , so that an operation of the heater increases the temperature of the photo sensor of said pixel , the method comprising:heating the at least one of the pixels by using the at least one heater, andthus increasing the temperature of this pixel by a larger degree than the temperature of at least a further one of the pixels.2. The method of claim 1 , wherein heating the at least one of the pixels aims at a local compensation of a temperature difference that is due to an operation of at least one integrated readout circuit and/or further integrated readout circuits.3. The method of further comprising:controlling the temperature locally by at least one integrated temperature sensor.4. The method of further comprising:controlling the temperature locally by at least one integrated temperature sensor. This application is the National Stage of International Application No. PCT/EP2015/061306, filed on May 21, 2015, and claims the benefit of European Application No. 14173903.7, filed on Jun. 25, 2014 and European Application No. 14170387.6, filed on May 28, 2014. The disclosures of the prior applications are incorporated herein by reference.Pictures produced by a semiconductor image sensor may show slight non-uniformities from pixel to pixel, which can be caused by local temperature differences in the sensor chip, because leakage current and responsivity of a photodiode depend on the temperature. To avoid this problem, image sensor chips are preferably operated at a ...

Sensor chip stack and method of producing a sensor chip stack

The sensor chip stack comprises a sensor substrate of a semiconductor material including a sensor, a chip fastened to the sensor substrate, the chip including an integrated circuit, electric interconnections between the sensor substrate and the chip, electric terminals of the chip, the chip being arranged between the electric terminals and the sensor substrate, and a molding material arranged adjacent to the chip, the electric terminals of the chip being free from the molding material.

Semiconductor image sensor with integrated pixel heating and method of operating a semiconductor image sensor

The semiconductor image sensor comprises a plurality of pixels (1) with photo sensors (2). At least one heater (4) is integrated with the photo sensors and is arranged in at least one of the pixels or in the vicinity of at least one of the pixels. An appropriate operation of the heater will increase the temperature of the relevant pixel. Thus it is possible to achieve a local compensation of a temperature difference that may be due to the operation of an integrated readout circuit (3) or any other integrated component generating heat.

1-AZA-BICYCLO[3.3.1]NONANES

The present invention relates to 1-aza-bicy-cloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R′); Y represents a group of formula, or wherein the left bond is attached to the A group and the right bond is attached to the R group; R represents a substituted or unsubstituted C-Caryl, substituted or unsubstituted hetero-C-Caryl, a group N(R)(R), or a group N(R)(CHPR); R represent a hydrogen, C-Calkyl, or CF; Rrepresents hydrogen, C-Calkyl, or CF; Rrepresents hydrogen, C-Calkyl, or CF; Rrepresents a substituted or unsubstituted C-Caryl or a substituted or unsubstituted C-Cheteroaryl; in free base or acid addition salt form. 2. (canceled)56-. (canceled)7. A pharmaceutical composition ,. comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the compound of in free base or pharmaceutically acceptable acid addition salt form, and'}a pharmaceutical carrier or diluent.89-. (canceled)10. A method for treating psychotic and neurodegenerative disorders , in a subject in need of such treatment , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering to such subject a therapeutically effective amount of the compound of in free base or pharmaceutically acceptable acid addition salt form.'}1112-. (canceled)13. A method for treating a disease or condition in which α7 nAChR activation plays a role or is implicated , in a subject in need of such treatment , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering to such subject a therapeutically effective amount of the compound of in free base or pharmaceutically acceptable acid addition salt form.'}14. A product obtained according to the process of wherein (−)-1-Aza-bicyclo[3.3.1]nonan-4-ol is used as starting material. The present invention relates to novel 1-aza-bicycloalkyl ...

CARBOXAMIDE DERIVATIVES

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; 111-. (canceled)13. The method according to or a pharmaceutically acceptable salt thereof claim 12 , wherein Ris iso-propyl claim 12 , cyclobutyl or cyclohexyl.14. The method according to or a pharmaceutically acceptable salt thereof claim 12 , wherein Ris cyclohexyl.17. The method according to which is selected from the group consisting of:1-(2-Chloro-4-methoxyphenyl)-N-(2-cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-methyl-1H-1,2,3-triazole-4-carboxamide;N-(2-Cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1-(2,4-dichlorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamide;N-(2-Cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1-(4-methoxy-2-(trifluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamide;N-(2-Cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1-(4-methoxy-3-methylphenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamide;1-(2-Chloro-4-(trifluoromethoxy)phenyl)-N-(2-cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-methyl-1H-1,2,3-triazole-4-carboxamide;1-(4-Chlorophenyl)-N-(2-cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-methyl-1H-1,2,3-triazole-4-carboxamide;1-(2,4-Dichlorophenyl)-N-(2-(2-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-methyl-1H-1,2,3-triazole-4-carboxamide;1-(4-Chlorophenyl)-N-(2-(2-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-methyl-1H-1,2,3-triazole-4-carboxamide;1-(2-Chloro-4-(trifluoromethoxy)phenyl)-N-(2-(2-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-methyl-1H-1,2,3-triazole-4-carboxamide;1-(2-Chloro-4-cyclopropylphenyl)-N-(2-cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-methyl-1H-1,2,3-triazole-4-carboxamide;1-(2-Chloro-4-cyclopropylphenyl)-N-(2-(2-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-methyl-1H-1,2,3-triazole-4-carboxamide;{'sub': '3', '1-(2-Chloro-4-cyclopropylphenyl ...

SENSOR CHIP STACK AND METHOD OF PRODUCING A SENSOR CHIP STACK

The sensor chip stack comprises a sensor substrate of a semiconductor material including a sensor, a chip fastened to the sensor substrate, the chip including an integrated circuit, electric interconnections between the sensor substrate and the chip, electric terminals of the chip, the chip being arranged between the electric terminals and the sensor substrate, and a molding material arranged adjacent to the chip, the electric terminals of the chip being free from the molding material. 1. A sensor chip stack , comprising:a sensor substrate of a semiconductor material including a sensor or plurality of sensors;a chip fastened to the sensor substrate, the chip including an integrated circuit;electric interconnections between the sensor substrate and the chip;electric terminals of the chip, the chip being arranged between the electric terminals and the sensor substrate; anda molding material arranged adjacent to the chip, the electric terminals of the chip being free from the molding material.2. The sensor chip stack according to claim 1 , further comprising:bond pads of the sensor substrate;contact pads of the chip, the contact pads facing the bond pads; andthe electric interconnections comprising pad connections, each of the pad connections electrically connecting one of the bond pads and one of the contact pads.3. The sensor chip stack according to claim 2 , whereinthe pad connections are via bumps.4. The sensor chip stack according to or claim 2 , further comprising:a contact layer of the chip, the contact layer being arranged between the sensor substrate and the chip; anda through-chip metallization penetrating the chip, the through-chip metallization contacting the contact layer and being electrically connected to one of the electric terminals.5. The sensor chip stack according to or claim 2 , further comprising:a contact pad of the sensor substrate, the contact pad being arranged between the sensor substrate and the chip; andthe electric interconnections ...

CARBOXAMIDE DERIVATIVES

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; 111-. (canceled)13. The method according to or a pharmaceutically acceptable salt thereof claim 12 , wherein Ris iso-propyl claim 12 , cyclobutyl or cyclohexyl.14. The method according to according to claim 12 , or a pharmaceutically acceptable salt thereof claim 12 , wherein Ris selected from 2 claim 12 ,2-dimethylpentyl claim 12 , 2 claim 12 ,2-dimethylpent-2-enyl claim 12 , cyclopentyl claim 12 , cyclohexyl claim 12 , cyclohexenyl claim 12 , tetrahydropyranyl claim 12 , dihydropyranyl claim 12 , dioxanyl claim 12 , tetrahydrofuranyl claim 12 , dioxolanyl and bicyclo[2.2.2]octanyl; wherein the cyclopentyl claim 12 , cyclohexyl claim 12 , cyclohexenyl claim 12 , tetrahydropyranyl claim 12 , dihydropyranyl claim 12 , dioxanyl claim 12 , tetrahydrofuranyl claim 12 , dioxolanyl or bicyclo[2.2.2]octanyl ring is unsubstituted or is substituted by one claim 12 , two claim 12 , three or four substituents R; and{'sup': '4', 'sub': 1', '4', '1', '4', '1', '4', '1', '4, 'each Ris independently selected from halo, (C-C)alkyl, halo(C-C)alkyl, (C-C)alkoxy, or halo(C-C)alkoxy; or'}{'sup': '4', 'two Rgroups, when attached to the same carbon atom, may be taken together with the carbon atom to which they are attached to form a tetrahydrofuran or dioxolane ring.'}16. The method according to claim 12 , or a pharmaceutically acceptable salt thereof claim 12 , wherein each Ris independently selected from methyl claim 12 , isopropyl claim 12 , tert-butyl and methoxy.17. The method according to claim 12 , which is selected from the group consisting of:[N-(2-Cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-(4-isopropylcyclohex-1-en-1-yl)-4-methylisoxazole-3-carboxamide];N-(2-Cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-(6-ethyl-4-methylcyclohex-1-en-1-yl)-4-methylisoxazole-3-carboxamide;N-(2-Cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-(6,6- ...

CARBOXAMIDE DERIVATIVES

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; 2. A compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris iso-propyl claim 1 , cyclobutyl or cyclohexyl.3. A compound according to according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris selected from 2 claim 1 ,2-dimethylpentyl claim 1 , 2 claim 1 ,2-dimethylpent-2-enyl claim 1 , cyclopentyl claim 1 , cyclohexyl claim 1 , cyclohexenyl claim 1 , tetrahydropyranyl claim 1 , dihydropyranyl claim 1 , dioxanyl claim 1 , tetrahydrofuranyl claim 1 , dioxolanyl and bicyclo[2.2.2]octanyl; wherein the cyclopentyl claim 1 , cyclohexyl claim 1 , cyclohexenyl claim 1 , tetrahydropyranyl claim 1 , dihydropyranyl claim 1 , dioxanyl claim 1 , tetrahydrofuranyl claim 1 , dioxolanyl or bicyclo[2.2.2]octanyl ring is unsubstituted or is substituted by one claim 1 , two claim 1 , three or four substituents R; and{'sup': '4', 'sub': 1', '4', '1', '4', '1', '4', '1', '4, 'each Ris independently selected from halo, (C-C)alkyl, halo(C-C)alkyl, (C-C)alkoxy, or halo(C-C)alkoxy; or'}{'sup': '4', 'two Rgroups, when attached to the same carbon atom, may be taken together with the carbon atom to which they are attached to form a tetrahydrofuran or dioxolane ring.'}5. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein each Ris independently selected from methyl claim 1 , isopropyl claim 1 , tert-butyl and methoxy.6. A compound according to which is selected from the group consisting of:[N-(2-Cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-(4-isopropylcyclohex-1-en-1-yl)-4-methylisoxazole-3-carboxamide];N-(2-Cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-(6-ethyl-4-methylcyclohex-1-en-1-yl)-4-methylisoxazole-3-carboxamide;N-(2-Cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-(6,6-dimethylcyclohex-1-en-1-yl)-4-methylisoxazole-3-carboxamide;[ ...

Carbamate/urea derivatives

The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

CARBOXAMIDE INHIBITORS

The present invention provides a compound of formula I 2. A compound according to claim 1 , wherein each Rindependently represents halo claim 1 , C-Calkyl claim 1 , C-Chaloalkyl claim 1 , C-Calkoxy claim 1 , (C-Calkoxy)C-Calkyl- claim 1 , C-Calkylthio claim 1 , C-Chaloalkoxy claim 1 , di(C-Calkyl)amino- claim 1 , C-Calkylamino- claim 1 , amino claim 1 , C-Ccycloalkyl claim 1 , (C-Ccycloalkyl)C-Calkyl- or (C-Ccycloalkyl)C-Calkoxy-; or two adjacent Rsubstituents may be taken together with the carbon atoms to which they are attached to form Het claim 1 , or Het2.3. A compound according to or claim 1 , wherein claim 1 , Rrepresents Br claim 1 , Cl claim 1 , F cyano claim 1 , methyl claim 1 , ethyl claim 1 , trifluoromethyl claim 1 , methoxy claim 1 , trifluoromethoxy or cyclopropyl.4. A compound according to any preceding claim claim 1 , wherein Rrepresents C-Calkyl.5. A compound according to any preceding claim claim 1 , wherein Rrepresents C-Calkyl.6. A compound according to any preceding claim claim 1 , wherein Rrepresents cyclohexyl claim 1 , or phenyl claim 1 , which cyclohexyl or phenyl is unsubstituted or substituted by one or two halo claim 1 , C-Calkyl claim 1 , C-Chaloalkyl claim 1 , C-Calkoxy or C-Chaloalkoxy groups.7. A compound according to any preceding claim claim 1 , wherein n represents 0.8. A pharmaceutical composition claim 1 , comprising:{'claim-ref': [{'@idref': 'CLM-00001', 'claims 1'}, {'@idref': 'CLM-00007', '7'}], 'a therapeutically effective amount of the compound according to any one of to , or a pharmaceutically acceptable salt thereof, and'}one or more pharmaceutically acceptable carriers.9. A pharmaceutical combination claim 1 , comprising:{'claim-ref': [{'@idref': 'CLM-00001', 'claims 1'}, {'@idref': 'CLM-00007', '7'}], 'a therapeutically effective amount of the compound according to any one of to , or a pharmaceutically acceptable salt thereof, and'}a second active agent.10. A method of treating pulmonary hypertension fibrosis; rheumatoid ...

CARBOXAMIDE INHIBITORS

The present invention provides a compound of formula I 2. The compound according to claim 1 , wherein m represents 1.3. The compound according to claim 1 , wherein n represents 0.5. The compound according to wherein claim 1 , Rrepresents H claim 1 , C-Calkyl claim 1 , C-Calkoxy claim 1 , or C-Chaloalkoxy.6. The compound according to claim 1 , wherein Rrepresents C-Ccycloalkyl claim 1 , or phenyl claim 1 , which phenyl is unsubstituted or substituted by one or two groups selected from halo claim 1 , C-Calkyl claim 1 , or C-Calkoxy.7. The compound according to wherein Rand Rrepresent C-Calkyl.8. A pharmaceutical composition claim 1 , comprising: a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt or co-crystal thereof claim 1 , and one or more pharmaceutically acceptable carriers.9. A pharmaceutical combination claim 1 , comprising: a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt or co-crystal thereof claim 1 , and a second active agent.10. A method of treating pulmonary hypertension claim 1 , such as pulmonary arterial hypertension claim 1 , fibrosis claim 1 , rheumatoid arthritis claim 1 , and fracture healing in a patient in need thereof claim 1 , comprising: administering to the subject in need thereof a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt or co-crystal thereof.1114-. (canceled)15. A method for treating a disease where Smurf-1 inhibitors have a beneficial effect claim 1 , comprising: administering an effective amount to of at least one compound according to or a pharmaceutically acceptable salt or co-crystal thereof to a subject in need of such treatment. The present invention describes organic compounds useful in therapy. The compounds demonstrate properties as selective Smurf-1 inhibitors and may thus be useful in the treatment of a range of disorders, particularly ...

CARBAMATE/UREA DERIVATIVES

The invention relates to compound of the formula I 2. A compound of formula I according to claim 1 , wherein Xis oxygen; or a salt thereof.3. A compound of formula I according to claim 1 , wherein p is 1 and q is 1; or a salt thereof.4. A compound of formula I according to claim 1 , wherein Ris isopropyl claim 1 , cyclopropyl claim 1 , cyclobutyl or cyclopentyl and m is 1; or a salt thereof.7. A compound of formula I according to claim 1 , wherein said compound is selected from the group consisting of1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate;1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate;1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate;1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclopropylpiperazine-1-carboxylate;1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate;1-(1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate;1-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate;1-(2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate;1-(2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate; and1-(6-oxo-1,6-dihydropyridin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate;or salts of these compounds.8. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to and one or more pharmaceutically acceptable carriers.9. A combination comprising a therapeutically effective amount of the compound according to and one or more therapeutically active agents.10. A method of treating a disorder or a disease in a subject mediated by H3 receptors claim 1 , wherein the method comprises administering to the subject a therapeutically effective amount of a compound according to .11. A compound according to claim 1 , for use as a ...

CARBAMATE/UREA DERIVATIVES

The invention relates to compound of the formula I 2. A compound of formula I according to claim 1 , wherein Xis oxygen; or a salt thereof.3. A compound of formula I according to claim 1 , wherein p is 1 and q is 1; or a salt thereof.4. A compound of formula I according to claim 1 , wherein Ris isopropyl claim 1 , cyclopropyl claim 1 , cyclobutyl or cyclopentyl and m is 1; or a salt thereof.7. A compound of formula I according to claim 1 , wherein said compound is selected from the group consisting of1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate;1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate;1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate;1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclopropylpiperazine-1-carboxylate;1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate;1-(1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate;1-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate;1-(2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate;1-(2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate; and1-(6-oxo-1,6-dihydropyridin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate;or salts of these compounds.8. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to and one or more pharmaceutically acceptable carriers.9. A combination comprising a therapeutically effective amount of the compound according to and one or more therapeutically active agents.10. A method of treating a disorder or a disease in a subject mediated by H3 receptors claim 1 , wherein the method comprises administering to the subject a therapeutically effective amount of a compound according to .11. A compound according to claim 1 , for use as a ...

CARBAMATE/UREA DERIVATIVES

The invention relates to compound of the formula I 117-. (canceled)18. A method of ameliorating disorders or conditions mediated through antagonism or inverse antagonism of the H3 receptor , wherein the disorder or condition is associated with impaired cognition; comprising administration of an effective amount of a compound selected from 1-(6-oxo-1 ,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate , 1-(1-methyl-6-oxo-1 ,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate , 1-(6-oxo-1 ,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate or 1-(1-methyl-6-oxo-1 ,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate or a salt thereof , to a subject in need of treatment thereof.19. A method according to wherein the cognitive function impairment disorder is Alzheimer's disease; comprising administration of an effective amount of 1-(6-oxo-1 claim 18 ,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate or a salt thereof.20. A method according to wherein the cognitive function impairment disorder is mild cognitive impairment comprising; administration of an effective amount of 1-(6-oxo-1 claim 18 ,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate or a salt thereof.21. A method according to wherein the cognitive function impairment disorder is Alzheimer's disease; comprising administration of an effective amount of 1-(1-methyl-6-oxo-1 claim 18 ,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate or a salt thereof.22. A method according to wherein the cognitive function impairment disorder is mild cognitive impairment comprising; administration of an effective amount of 1-(1-methyl-6-oxo-1 claim 18 ,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate or a salt thereof.23. A method according to wherein the cognitive function impairment disorder is Alzheimer's disease comprising; ...

CARBOXAMIDE DERIVATIVES

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; 2. A compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris iso-propyl claim 1 , cyclobutyl or cyclohexyl.3. A compound according to according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris selected from 2 claim 1 ,2-dimethylpentyl claim 1 , 2 claim 1 ,2-dimethylpent-2-enyl claim 1 , cyclopentyl claim 1 , cyclohexyl claim 1 , cyclohexenyl claim 1 , tetrahydropyranyl claim 1 , dihydropyranyl claim 1 , dioxanyl claim 1 , tetrahydrofuranyl claim 1 , dioxolanyl and bicyclo[2.2.2]octanyl; wherein the cyclopentyl claim 1 , cyclohexyl claim 1 , cyclohexenyl claim 1 , tetrahydropyranyl claim 1 , dihydropyranyl claim 1 , dioxanyl claim 1 , tetrahydrofuranyl claim 1 , dioxolanyl or bicyclo[2.2.2]octanyl ring is unsubstituted or is substituted by one claim 1 , two claim 1 , three or four substituents R; and{'sup': '4', 'sub': 1', '4', '1', '4', '1', '4', '1', '4, 'each Ris independently selected from halo, (C-C)alkyl, halo(C-C)alkyl, (C-C)alkoxy, or halo(C-C)alkoxy; or'}{'sup': '4', 'two Rgroups, when attached to the same carbon atom, may be taken together with the carbon atom to which they are attached to form a tetrahydrofuran or dioxolane ring.'}5. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein each Ris independently selected from methyl claim 1 , isopropyl claim 1 , tert-butyl and methoxy.7. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.8. A combination comprising a therapeutically effective amount of a compound according to or a pharmaceutically acceptable salt thereof and one or more therapeutically active agents.9. A method of modulating Smurf-1 activity in a subject claim 1 , wherein the method ...

CARBOXAMIDE DERIVATIVES

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;

CARBOXAMIDE DERIVATIVES

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt or co-crystal thereof;

CARBOXAMIDE DERIVATIVES

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; 2. A compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris iso-propyl claim 1 , cyclobutyl or cyclohexyl.3. A compound according to according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris selected from 2 claim 1 ,2-dimethylpentyl claim 1 , 2 claim 1 ,2-dimethylpent-2-enyl claim 1 , cyclopentyl claim 1 , cyclohexyl claim 1 , cyclohexenyl claim 1 , tetrahydropyranyl claim 1 , dihydropyranyl claim 1 , dioxanyl claim 1 , tetrahydrofuranyl claim 1 , dioxolanyl and bicyclo[2.2.2]octanyl; wherein the cyclopentyl claim 1 , cyclohexyl claim 1 , cyclohexenyl claim 1 , tetrahydropyranyl claim 1 , dihydropyranyl claim 1 , dioxanyl claim 1 , tetrahydrofuranyl claim 1 , dioxolanyl or bicyclo[2.2.2]octanyl ring is unsubstituted or is substituted by one claim 1 , two claim 1 , three or four substituents R; and{'sup': '4', 'sub': 1', '4', '1', '4', '1', '4', '1', '4, 'each Ris independently selected from halo, (C-C)alkyl, halo(C-C)alkyl, (C-C)alkoxy, or halo(C-C)alkoxy; or'}{'sup': '4', 'two Rgroups, when attached to the same carbon atom, may be taken together with the carbon atom to which they are attached to form a tetrahydrofuran or dioxolane ring.'}5. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein each Ris independently selected from methyl claim 1 , isopropyl claim 1 , tert-butyl and methoxy.6. A compound according to which is selected from the group consisting of:[N-(2-Cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-(4-isopropylcyclohex-1-en-1-yl)-4-methylisoxazole-3-carboxamide];N-(2-Cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-(6-ethyl-4-methylcyclohex-1-en-1-yl)-4-methylisoxazole-3-carboxamide;N-(2-Cyclohexyl-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-(6,6-dimethylcyclohex-1-en-1-yl)-4-methylisoxazole-3-carboxamide;[ ...

Pyrrolidine and piperidine acetylene derivatives for use as mglur5 antagonists

The invention provides Compounds of formula (I) wherein the substituents are as defined in the description, processes and intermediates for their preparation and their use as pharmaceuticals in the treatment of disorders mediated by mGluR5.

Acetylene Derivatives

The invention provides compounds of formula (I) wherein the substituents are as defined in the specification, to processes for their preparation and corresponding intermediates, and their use as pharmaceuticals.

Acetylene Derivatives

The invention provides compounds of formula (I), wherein the substituents are as defined in the specification, to processes for their preparation and their use as pharmaceuticals.

Acetylene derivatives

The invention provides compounds of formula (I) wherein R 1 represents hydrogen or alkyl; R 2 represents an unsubstituted or substituted heterocycle or R 2 represents an unsubstituted or substituted aryl; R 3 represents alkyl or halogen; X represents a single bond or an alkandiyl-group, optionally interrupted by one or more oxygen atoms or carbonyl groups or carbonyloxy groups in free base or acid addition salt form, processes for their preparation and their use as pharmaceuticals.

Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists

The invention provides compounds of formula (I) wherein the substituents are as defined in the description, processes and intermediates for their preparation and their use as pharmaceuticals.

Acetylene derivatives

The invention provides compounds of formula (I) wherein R 1 represents hydrogen or alkyl; R 2 represents an unsubstituted or substituted heterocycle or R 2 represents an unsubstituted or substituted aryl; R 3 represents alkyl or halogen; X represents a single bond or an alkandiyl-group, optionally interrupted by one or more oxygen atoms or carbonyl groups or carbonyloxy groups in free base or acid addition salt form, processes for their preparation and their use as pharmaceuticals.

PIPERAZINE DERIVATIVES WITH SST1 ANTAGONISTIC EFFECT

Phenylacetylene derivatives having mglur5 receptor affinity

The invention provides compounds of formula (I) wherein the substituents are as defined in the specification, to processes for their preparation and corresponding intermediates, and their use as modulators of the mglu5 receptor.

ACETYLENE DERIVATIVES

L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I) DANS LAQUELLE R1 REPRÉSENTE HYDROGÈNE OU ALKYLE; R2 DÉSIGNE UN HÉTÉROCYCLE NON SUBSTITUÉ OU SUBSTITUÉ OU R2 REPRÉSENTE UN ARLYE NON SUBSTITUÉ OU SUBSTITUÉ; R3 DÉSIGNE ALKYLE OU HALOGÈNE ; X REPRÉSENTE UNE LIAISON SIMPLE OU UN GROUPE ALKANDIYL, ÉVENTUELLEMENT INTERROMPU PAR UN OU PLUSIEURS ATOMES D'OXYGÈNE OU DES GROUPES CARBONYLE OU DES GROUPES CARBONYLOXY DANS UNE BASE LIBRE OU UNE FORME DE SEL D'ADDITION ACIDE, DES PROCÉDÉS DE PRÉPARATION ET D'UTILISATION DE CEUX-CI COMME PRODUITS PHARMACEUTIQUES. The invention relates to compounds of formula (I) in which R.sup.1 represents hydrogen or alkylene; R2 NAMES A NON-SUBSTITUTED OR SUBSTITUTED HETEROCYCLE OR R2 REPRESENTS AN UN SUBSTITUTED OR SUBSTITUTED ARLY; R3 DESIGNATED ALKYL OR HALOGEN; X REPRESENTS A SINGLE BINDING OR AN ALKANDIYL GROUP, WHICH IS POSSIBLY INTERRUPTED BY ONE OR MORE OXYGEN ATOMS OR CARBONYL GROUPS OR CARBONYLOXY GROUPS IN A FREE BASE OR ACID ADDITION SALT FORM, METHODS OF PREPARATION AND USE THESE AS PHARMACEUTICAL PRODUCTS.

DERIVATIVES OF 3- (HETEROARIL-OXI) -2-ALQUIL-1-AZA-BICICLOALQUILO AS LIGANDOS ALFA.7-NACHR FOR THE TREATMENT OF CNS DISEASES.

Un compuesto de fórmula I **Fórmula** en donde A representa hidrógeno, B representa metilo y B está en la posición trans con respecto al oxígeno; X representa CH2; Y representa un grupo de fórmula **Fórmula** en donde el enlace izquierdo está unido al oxígeno y el enlaza derecho está unido el grupo R; R representa 5-indolilo; en forma de base libre o de una sal de adición ácida.

Carbamate / urea derived compounds, histamine h3 receptor inhibitors; preparation procedure; intermediate compound; pharmaceutical composition; pharmaceutical combination; and use in the treatment of narcolepsy.

3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nachr ligands for the treatment of cns diseases.

Acetylene derivatives

Carbamate/urea derivatives

Carbamate/urea derivatives

The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

Carboxamide derivatives

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt or co-crystal thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Beta-carboline derivatives and its pharmaceutical use against depression and anxiety

The invention provides compounds of formula (I) wherein R1 to R5 are as defined in the description, and their preparation. The compounds of formula (I) are useful as pharmaceuticals.

acetylene derivatives

DERIVADOS DE ACETILENO. A presente invenção refere-se a compostos de fórmula (I) em que R˜ representa hidrogênio ou alquila; R representa um heterociclo não substituído ou substituído ou R representa uma arila não substituida ou substituida; R representa alquíla ou halogeno; X representa uma ligação única ou um grupo aícandiila, opcionalmente interrompido por um ou mais átomos de oxigênio ou grupos carbonila ou grupos carbonílóxi em forma de sal de adição de ácido ou base livre, processos para sua preparação e seu uso como farmacêuticos. ACETYLENE DERIVATIVES. The present invention relates to compounds of formula (I) in which R represents hydrogen or alkyl; R represents an unsubstituted or substituted heterocycle or R represents an unsubstituted or substituted aryl; R represents alkyl or halo; X represents a single bond or an alkandyyl group, optionally interrupted by one or more oxygen atoms or carbonyl groups or carbonyloxy groups in acid addition salt or free base form, processes for their preparation and their use as pharmaceuticals.

Semiconductor image sensor with integrated pixel heating and method of operating a semiconductor image sensor

1-aza-bicyclo[3.3.1]nonanes

THE PRESENT INVENTION RELATES TO 1-AZA-BICYCLOALKYL DERIVATIVES OF FORMULA (?) WHEREIN THE SUBSTITUENTS ARE AS DEFINED IN THE SPECIFICATION, TO PROCESSES FOR THEIR PRODUCTION, THEIR USE AS PHARMACEUTICALS AND TO PHARMACEUTICAL COMPOSITIONS COMPRISING THEM.

Radiation-hardened package for an electronic device and method of producing a radiation-hardened package

The package includes a carrier (1) and an electronic device (2) on the carrier. A nanomaterial is provided for improved X-ray radiation hardness. A cover (3) or part of a cover (3), which is applied over the electronic device, is at least partially made from nanomaterial. The cover may be a glob top or an injection-molded cover.

Beta-carboline derivatives, process for their preparation, their use and pharmaceutical compositions containing them

A találmány tárgyát az (I) általános képlet szerinti vegyületek, aholR1-R5 az alábbiakban definiált csoportok, és ezek előállítása képezik.Az (I) általános képlet vegyületei gyógykészítményként hasznosíthatóvegyületek. A találmány kiterjed a vegyületeket tartalmazógyógyszerkészítményekre is. Az (I) képlet szerinti vegyület, ahol R1az (a), (b), (c), (d), (e), (f), (g), (h) és (i) képleteknek megfelelőcsoport, ahol R6 egy 1-4 szénatomos alkilcsoport, R7 és R8 egymástólfüggetlenül egy hidrogénatom vagy 1-4 szénatomos alkilcsoport és X egyhidrogénatom, 1-4 szénatomos alkoxicsoport, 1-4 szénatomos alkil-amino- vagy di-1-4 szénatomos alkil-amino-csoport, R2 és R3 egymástólfüggetlenül 1-4 szénatomos alkoxi-1-4 szénatomos alkil- vagy 3-7szénatomos cikloalkil-1-4 szénatomos alkil-, vagy feltéve, hogy R1 nemegy opcionálisan szubsztituált fenilcsoport, 1-12 szénatomosalkilcsoport, R4 egy hidrogénatom, 1-4 szénatomos alkil-, 1-4szénatomos alkoxicsoport, halogénatom vagy trifluormetilcsoport és R5egy hidrogénatom vagy 1-4 szénatomos alkilcsoport. Ó The present invention relates to compounds of formula (I), wherein R1 to R5 are the groups defined below, and their preparation. The compounds of formula (I) are useful as pharmaceutical compositions. The invention also relates to pharmaceutical compositions containing the compounds. A compound of formula (I) wherein R 1 is a group of formulas (a), (b), (c), (d), (e), (f), (g), (h) and (i), wherein R 6 a C 1 -C 4 alkyl group, R 7 and R 8 independently of one another hydrogen or C 1 -C 4 alkyl and X monohydrogen, C 1 -C 4 alkoxy, C 1 -C 4 alkylamino or di-C 1 -C 4 alkylamino, R2 and R3 are independently C1-C4 alkoxy-C1-C4 alkyl or C3-C7 cycloalkyl-C1-C4 alkyl, or provided that R1 is not optionally substituted phenyl, C1-C12 alkyl, R4 is hydrogen, C1-C4 alkyl, C1-C4 alkoxy, halogen or trifluoromethyl and R5 is hydrogen or C1-C4 alkyl. SHE

Novel dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof

The present invention pertains to compounds of formula (I) wherein X is O, NH, N(C1-4)alkyl, CO or CHOH, Y is CH or N, A and B are each hydrogen or together form a second bond between the carbon atoms to which they are attached, R1 is hydrogen or (C1-4)alkyl, R2 is optionally substituted (C1-8)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, aryl or heteroaryl, R3 is CH(Re)CONRaRb or (CH2)nNRc,Rd, n is 0, 1 or 2, Ra, Rb, Rc and Rd, independently, are hydrogen or optionally substituted (C1-8)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, (C7-9)bicycloalkyl, 1-aza-(C7-9)bicycloalkyl, aryl, aryl(C1-4)alkyl, heteroaryl, heteroaryl(C1-4)alkyl or heterocyclyl, or Ra, Rb, Rc and Rd, together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, piperidino, morpholino or piperazinyl group, Re is (C1-8)alkyl, (C1-4)alkoxy(C1-4)alkyl, (C3-7)cycloalkyl or (C3-7)cycloalkyl(C1-4)alkyl, and R4, R5, R6, R7, R8 and R9, independently, are hydrogen, (C1-4)alkyl, (C1-4)alkoxy, (C1-4)alkyl-SO2, cyano, nitro or halogen; to a process for the preparation of such compounds of formula (I), their use as a pharmaceuticals, especially in the treatment of neurological and vascular disorders related to beta-­amyloid generation and/or aggregation, and to pharmaceutical compositions and combinations comprising such compounds of formula (I).

Substituted piperidine derivatives as somatostatin sst1 receptor antagonists

Compound of the formula (I) wherein R1, R2, n and m are as defined in the specification. The compounds of formula (I) are somatostatin sst1 receptor antagonists.

Carboxamide derivatives

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt or co-crystal thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Carboxamide derivatives

La présente invention concerne un composé de formule (i) ou un sel pharmaceutiquement acceptable de celui-ci; un procédé de fabrication de composés de l'invention et leurs utilisations thérapeutiques. La présente invention concerne, en outre, une combinaison de principes pharmacologiquement actifs et une composition pharmaceutique. The present invention relates to a compound of formula (i) or a pharmaceutically acceptable salt thereof; a process for the manufacture of compounds of the invention and their therapeutic uses. The present invention further relates to a combination of pharmacologically active principles and a pharmaceutical composition.

Piperazine derivatives having sst1 antagonistic activity

The invention provides compounds of formula (I), wherein X, R1 and R2 are as defined in the description, and their preparation. The compounds of formula (I) are useful as pharmaceuticals.

1-aza-bicyclo[3.3.1]nonanes

The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R1); Y represents a group of formula, or wherein the left bond is attached to the A group and the right bond is attached to the R group; R represents a substituted or unsubstituted C5- C10aryl, substituted or unsubstituted hetero-C5-C10aryl, a group N(R1)(R4), or a group N(R2)(CHP3R4); R represent a hydrogen, C1-C4alkyl, or CF3; R2 represents hydrogen, C1-C4alkyl, or CF3; R3 represents hydrogen, C1-C4alkyl, or CF3; R4 represents a substituted or unsubstituted C5-C10 aryl or a substituted or unsubstituted C5-C10heteroaryl; in free base or acid addition salt form.

Phenylacetylene derivatives having mglur5 receptor affinity

The invention provides compounds of formula (I) wherein the substituents are as defined in the specification, to processes for their preparation and corresponding intermediates, and their use as modulators of the mglu5 receptor.

Semiconductor device for indirect detection of electromagnetic radiation and method of production

The semiconductor device comprises a substrate of semiconductor material having a main surface, an integrated circuit in the substrate, a photodetector element or array of photodetector elements arranged at or above the main surface, and at least one nanomaterial film arranged above the main surface. At least part of the nanomaterial film has a scintillating property. The method of production includes the use of a solvent to apply the nanomaterial film, in particular by inject printing, by silk-screen printing, by spin coating or by spray coating.

Pyrrolidine and piperidine acetylene derivatives for use as mglur5 antagonists

The invention provides Compounds of formula (I) wherein the substituents are as defined in the description, processes and intermediates for their preparation and their use as pharmaceuticals in the treatment of disorders mediated by mGluR5.

Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof

The present invention pertains to novel dibenzo[b,f]oxepine-10-carboxamides compound to a process for the preparation of such compounds of formula I, their use as a pharmaceuticals, especially in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation, and to pharmaceutical compositions and combinations comprising such compounds of formula I.

Carboxamide derivatives

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

BETA-CARBOLINE DERIVATIVES AND PHARMACEUTICAL USE AGAINST DEPRESSION AND ANXIETY.

Compuesto que es (R)-1,1-bis-etoximetil-3-(4-fenil-1H-imidazol-2-il)-2,3,4,9-tetrahidro-1H-ß-carbolina, en forma de sal de adición de ácido o base libre. Compound which is (R) -1,1-bis-ethoxymethyl-3- (4-phenyl-1H-imidazol-2-yl) -2,3,4,9-tetrahydro-1H-β-carboline, in the form of acid addition salt or free base.

3- (HETEROARYLOXY) -2-ALKYL-1-AZABICYCLOALKYL DERIVATIVES AS ALPHA.7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES

Dihydroindole derivatives useful in parkinson's disease

The invention relates to novel heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Beta-carboline derivatives and its pharmaceutical use against depression and anxiety

Decahydro-isoquinolines

The invention provides compounds of for-mula (I), wherein A, B and R are as defined in the descrip-tion, and the preparation thereof. The compounds of formula (I) are useful as somatostatin receptor antagonists.

Phenylacetylene derivatives having mglur5 receptor affinity

PHENYLACETYLENE DERIVATIVES WITH AFFINITY TO THE MGLUR5 RECEPTOR

Macrocyclic lactams and pharmaceutical use thereof

The present invention relates to novel macrocyclic compounds of the formula (I) wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharma~ceutical compositions comprising them.

1-Aza-bicyclo[3.3.1]nonanes

Disclosed is an aza-bicyclononane compound of formula I wherein A represents O or N(R1); R1 represents hydrogen, C1-C4alkyl, or CF3-, and wherein the rest of the substituents are disclosed in the specification. Also disclosed is the use of a compound of formula I for the manufacture of a medicament for the prevention and treatment of psychotic and neurodegenerative disorders or diseases or conditions in which alpha7 nAChR activation plays a role or is implicated.

Decahydro-isoquinoline

Carboxamide derivatives

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Carbamate/urea derivatives

The invention relates to a compound of the formula (l), or a salt thereof; to its preparation, to its use as medicament and to medicaments comprising it. More specifically, the invention relates to a novel class of H3 receptor antagonists which are useful in the treatment of disorders and diseases mediated by H3 receptors, particularly narcolepsy. (see formula I)

Carboxamide derivatives

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt or co-crystal thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Piperazine derivatives having sst1 antagonistic activity

The invention provides compounds of formula (I), wherein X, R1 and R2 are as defined in the description, and their preparation. The compounds of formula (I) are useful as pharmaceuticals.

Carboxamide derivatives

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Acetylene derivatives

The invention provides compounds of formula (I), wherein the substituents are as defined in the specification, to processes for their preparation and their use as pharmaceuticals.

Piperazine derivatives having sst1 antagonistic activity

Decahydro-isoquinolines

The invention provides compounds of formula (I), wherein A, B and R are as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as somatostatin receptor antagonists.

Acetylenderivate

Hydantoin derivatives with affinity for somatostatin receptors

The invention provides compounds of formula (I) wherein X, Y, R<SUB>1</SUB>, R<SUB>2</SUB>, R<SUB>3 </SUB>and R<SUB>4 </SUB>are as defined in the description, and the preparation thereof. The compounds of the formula bind to somatostatin receptors and are useful as pharmaceuticals

Hydantoin derivate mit affinität für somatostatin rezeptoren

Phenylacetylenderivate mit affinitat zum mglur5- rezeptor

Neue dibenzoäb,füoxepin-10-carbonsäureamide und deren pharmazeutische anwendungen

Beta-carbolinderivate und deren pharmazeutische verwendung gegen depression und angst

Carboxamide derivatives

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Hydantoin derivate mit affinität für somatostatin rezeptoren

1-aza-bicycloä3.3.1ünonane

Piperazine derivatives having sst1 antagonistic activity

Acetylenderivate

Carboxamide derivatives

The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Substituierte piperidin-derivate als somatostatin-sst1-rezeptorantagonisten

Interleukin-17 inhibitors

The present invention relates to novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds that are Interleukin-17 (IL-17) inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by IL-17.

Piperazin derivate mit sst1 antagonistischer wirkung

Hydantoin derivsatives with affinity for somatostatin receptors

The invention provides compounds of formula (I) wherein X, Y, R 1 , R 2 , R 3 and R 4 are as defined in the description, and the preparation thereof. The compounds of the formula bind to somatostatin receptors and are useful as pharmaceuticals.

Hydantoin derivatives with affinity for somatostatin receptors

The invention provides compounds of formula (I) wherein X, Y, R<SUB>1</SUB>, R<SUB>2</SUB>, R<SUB>3 </SUB>and R<SUB>4 </SUB>are as defined in the description, and the preparation thereof. The compounds of the formula bind to somatostatin receptors and are useful as pharmaceuticals

Inhibidores de interleucina-17

La presente invención se refiere a nuevos compuestos de 2-formamido (N-fenil y N-piridil) acetamida sustituidos con N-óxidos de piridina que son inhibidores de interleucina-17 (IL-17), a procesos para su preparación, composiciones farmacéuticas, y medicamentos que los contienen, y a su uso en enfermedades y trastornos mediados por IL-17. Reivindicación 1: Un compuesto de la fórmula [1] en donde, R¹ es un compuesto de fórmula [2] ó [3] en donde, R⁶ en cada ocurrencia se selecciona entre H, F, Cl, alquilo C₁₋₃ y fluoroalquilo C₁₋₃; R⁷ en cada ocurrencia se selecciona entre H, F, Cl, alquilo C₁₋₃ y fluoroalquilo C₁₋₃; R⁸ se selecciona entre H, halo, alquilo C₁₋₃ e hidroximetilo; X es C o N y cuando X es N, R³ está ausente; R² se selecciona entre H y F; R³ se selecciona entre H, F y Cl; R⁴ se selecciona entre H y F; R⁵ es un heteroarilo de 5 miembros que comprende 1 ó 2 heteroátomos independientemente seleccionados entre N, S, y O, y en donde dicho heteroarilo es insustituido o sustituido con uno o dos grupos independientemente seleccionados entre alquilo C₁₋₃ y cicloalquilo C₃₋₄, en donde dicho alquilo C₁₋₃ es insustituido o sustituido con uno o más grupos independientemente seleccionados entre F, OH, alcoxi C₁₋₃, -C(O)OH y NR¹ᵇR¹ᶜ, en donde R¹ᵇ y R¹ᶜ son independientemente seleccionados entre H y alquilo C₁₋₃; o R⁵ es un heteroarilo de 5 miembros que comprende un átomo de N en donde dicho heteroarilo de 5 miembros se fusiona a un heterociclo de 6 miembros que comprende un átomo de N en donde dicho heterociclo es insustituido o sustituido con un grupo seleccionado entre alquilo C₁₋₃, alcoxi C₁₋₃ alquilo C₁₋₃, -C(O)alquilo C₁₋₃, cicloalquilo C₃₋₄ y oxetanilo; Z es un resto de fórmula [4], en donde R⁹ se selecciona entre (1) cicloalquilo C₅₋₈ monocíclico y bicicloalquilo C₆, cada uno de los cuales es independientemente insustituido o sustituido con uno o más grupos independientemente seleccionados en cada ocurrencia entre fluoro, alquilo C₁₋₃ y fluoroalquilo C₁₋₃, y en ...

Inhibidores de interleucina-17

La presente invención se refiere a nuevos compuestos de 2-formamido (N-fenil y N-piridil) acetamida sustituidos con N-óxidos de piridina que son inhibidores de interleucina-17 (IL-17), a procesos para su preparación, composiciones farmacéuticas, y medicamentos que los contienen, y a su uso en enfermedades y trastornos mediados por IL-17.

Interleukin-17 inhibitors

The present invention relates to novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds that are Interleukin-17 (IL-17) inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by IL-17.

Interleukin-17 inhibitors

The present invention relates to novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds that are Interleukin-17 (IL-17) inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by IL-17.

Inhibidores de interleucina-17

La presente invencion se refiere a compuestos de 2-formamido (N-fenil y N-piridil) acetamida sustituidos con N-oxidos de piridina que son inhibidores de interleucina-17 (IL-17) de formula (I), donde R1 es (a) o (b); R6 es H, F, Cl, alquilo C1-C3 o fluoroalquilo C1-C3; R7 es H, F, Cl, alquilo C1-C3 o fluoroalquilo C1-C3; R8 es H, halo, alquilo C1-C3 o hidroximetilo; X es C o N y cuando X es N, R3 esta ausente; R2 se selecciona entre H y F; R3 es H, F o Cl; R4 es H o F; R5 es un heteroarilo de 5 miembros que comprende 1 o 2 heteroatomos seleccionados entre N, S, y O, y en donde dicho heteroarilo es insustituido o sustituido con uno o dos grupos seleccionados entre alquilo C1-C3 y cicloalquilo C3-C4, en donde dicho alquilo C1-C3 es insustituido o sustituido con uno o mas grupos seleccionados entre F, OH, alcoxi C1-C3, -C(O)OH y NR1bR1c, en donde R1b y R1c son H o alquilo C1-C3; o R5 es un heteroarilo de 5 miembros que comprende un atomo de N en donde dicho heteroarilo de 5 miembros se fusiona a un heterociclo de 6 miembros que comprende un atomo de N en donde dicho heterociclo es insustituido o sustituido con un grupo seleccionado entre alquilo C1-C3, alcoxi C1-C3 alquilo C1-C3, -C(O)alquilo C1-C3, cicloalquilo C3-C4 y oxetanilo; Z es -CHR)-; R9 es cicloalquilo C5-C8 monociclico, bicicloalquilo C6, entre otros. Son compuestos preferidos: 2,4-dimetil-3-(4-((S)-2-(1-metil-1H-pirazol-5-carboxamido)-2-((S)-1,2,3,4-tetrahidronaftalen-1-il)acetamido)fenil)piridina 1-oxido; 4-cloro-3-(4-((S)-2-ciclohexil-2-(1-metil-1H-pirazol-5-carboxamido)acetamido)-2-fluorofenil)-2-metilpiridina 1-oxido; 2,4-dimetil-3-(4-((S)-2-(1-metil-1H-pirazol-5-carboxamido)-2-((1r,4S)-4-metilciclohexil)acetamido)fenil)piridina 1-oxido; entre otros.

Inhibidores de interleucina-17.

La presente invención se refiere a nuevos compuestos de 2-formamido (N-fenil y N-piridil) acetamida sustituidos con N-óxidos de piridina que son inhibidores de interleucina-17 (IL-17), a procesos para su preparación, composiciones farmacéuticas, y medicamentos que los contienen, y a su uso en enfermedades y trastornos mediados por IL-17.

Inhibidores de interleucina-17

La presente invención se refiere a nuevos compuestos de 2-formamido (N-fenil y N-piridil) acetamida sustituidos con N-óxidos de piridina que son inhibidores de interleucina-17 (IL-17), a procesos para su preparación, composiciones farmacéuticas, y medicamentos que los contienen, y a su uso en enfermedades y trastornos mediados por IL-17.

Inhibidores de interleucina-17

La presente invención se refiere a nuevos compuestos de 2-formamido (<em>N</em>-fenil y <em>N</em>-piridil) acetamida sustituidos con N-óxidos de piridina que son inhibidores de interleucina-17 (IL-17), a procesos para su preparación, composiciones farmacéuticas, y medicamentos que los contienen, y a su uso en enfermedades y trastornos mediados por IL-17

Inhibidores de interleucina-17

La presente invención se refiere a nuevos compuestos de 2-formamido (N-fenil y N-piridil) acetamida sustituidos con N-óxidos de piridina que son inhibidores de interleucina-17 (IL-17), a procesos para su preparación, composiciones farmacéuticas, y medicamentos que los contienen, y a su uso en enfermedades y trastornos mediados por IL-17.